🌬️ The new offering provides clinical and commercial manufacturing services at a kilogram scale.
💊 The administration of protein-based therapies for respiratory diseases can be improved through the local delivery method of a solid protein formulation to the lungs.
🌍 Shelf-stable dry powder inhalers also improve patient access and reduce reliance on cold chain logistics.
💪 Lonza’s new clinical offering strengthens their spray-drying expertise and manufacturing capacity for pulmonary delivery.
Introduction:
Lonza has announced an expansion of its service offering for the spray-drying of proteins for pulmonary delivery. With the growing prevalence of biologics in the respiratory drug pipeline, this new offering aims to provide a viable alternative to traditional administration methods for respiratory disease treatments.
- The respiratory drug pipeline has seen a shift towards biologics, with approximately 30% of therapies now being biologics and an expected increase to 50% by 2030.
- Historically, protein-based therapies for respiratory diseases have been limited to intravenous or subcutaneous injections, requiring frequent and costly administration.
- Spray-drying of proteins for pulmonary delivery offers a focused and local delivery method that can reduce dose and off-target exposure.
- The use of dry powder inhalers also improves patient access to therapy by reducing reliance on cold chain logistics.
- Lonza’s expanded service offering strengthens their spray-drying expertise and provides manufacturing capacity from early-phase to commercial supply.
Conclusion:
With the increasing prevalence of biologics in the respiratory drug pipeline, the expansion of Lonza’s service offering for the spray-drying of proteins for pulmonary delivery is a significant development. This offering provides a more convenient and cost-effective method for administering protein-based therapies for respiratory diseases, ultimately improving patient access and compliance. The ability to scale manufacturing from early-phase to commercial supply further supports the development and accessibility of these innovative therapies.
